Ucwaningo Olusha Luthola Ukufa Komdlavuza Webele Kwenyuka Emhlabeni Wonke

Ngokusho kweResearch and Markets, imakethe yomhlaba wonke yezidakamizwa zomdlavuza webele kulindeleke ukuthi ikhule iye ku- $19.49 billion ngo-2025 ku-CAGR ka-7.1%. Phakathi konjiniyela be-biotech abasebenza ngo-2022 ekwelapheni okusha komdlavuza webele kukhona i-Oncolytics Biotech Inc., i-Roche Holding AG, i-Pfizer Inc., i-Incyte Corporation, ne-AstraZeneca PLC.

Phakathi komdlavuza okuhloswe ngawo i-Oncolytics Biotech Inc. kanye ne-flagship immunotherapeutic ejenti i-pelareorep, umdlavuza webele yinto egxile kakhulu enkampanini, ngokwencwadi yayo yakamuva eya kubanikazi bamasheya ebuyekeze impumelelo yayo ngo-2021 futhi yaveza uhlelo lwayo oluzayo luka-2022.

Ngaphakathi kohlelo lwayo Lomdlavuza Webele kuze kube manje, i-Oncolytics ibone ukusinda okuphindwe ngaphezu kokuphindwe kabili kweziguli ezinomdlavuza webele we-metastatic HR+/HER2- elashwa nge-pelareorep ku-IND-213-njengoba kubonwe emiphumeleni yocwaningo eyethulwa ngo-2017.

Ngemva kokuhlaziya idatha okwengeziwe, i-Oncolytics ikhethe ukugxila ezinhlosweni ezintathu ezingafinyeleleka ezibekwe abalawuli nabalingani be-pharma benkampani, abamele izinyathelo ezibalulekile eziya ocwaningweni lokubhalisa. Lokhu kwakuhlanganisa: 1. Ukuqinisekisa ukuthi i-pelareorep isebenza ngendlela ye-immunotherapeutic yokwenza; 2. Ukunquma ukuthi i-pelareorep iyasebenzisana yini nama-immune checkpoint inhibitors; kanye 3. Nokuhlonza i-biomarker ukukhetha iziguli okungenzeka zibe nemiphumela engcono yomtholampilo.

Kusukela ngo-Ephreli 2021, i-Oncolytics yethule idatha yeqembu evela ocwaningweni lwayo lwe-AWARE-1, olwenziwa ne-Roche Holding AG (OTC:RHHBY), okubonisa ukuthi inkampani izuze izinjongo ezimbili zokuqala ezishiwo ngenhla.

Kamuva ngoDisemba eSan Antonio Breast Cancer Symposium (SABCS) ka-2021, i-Oncolytics yethula isibuyekezo esihle sokuphepha esivela ku-IRENE Isigaba sesi-2 Sokuhlolwa Komdlavuza Webele Kathathu Negative Okuhlola ukuphepha nokusebenza ngempumelelo kwe-pelareorep ngokuhambisana ne-anti-PD-1 checkpoint inhibitor. i-retifanlimab evela ku-Incyte Corporation yokwelashwa komugqa wesibili noma wesithathu weziguli ezinomdlavuza webele we-metastatic triple-negative (TNBC).

Idatha yokuphepha evela ocwaningweni ibonise ukuthi inhlanganisela ibekezelelwe kahle, ngaphandle kokukhathazeka kokuphepha okuphawulwe kunoma yiziphi iziguli ezibhalise ocwaningweni ngesikhathi sokubika.

Ucwaningo lwe-IRENE lusaqhubeka futhi luzoqhubeka nokubhalisa iziguli e-Rutgers Cancer Institute yaseNew Jersey nase-Ohio State University Comprehensive Cancer Centre.

I-Incyte Corporation isanda kunikeza esinye isibuyekezo esihilela i-retifanlimab yayo ngokuhlangana nekhandidethi elihola phambili le-BriaCell Therapeutics'emtholampilo i-Bria-IMTTM kwa-SABCS. Ngokufingqiwe ekubuyekezweni, ukusinda okuphelele kwakuphakeme kakhulu ezigulini esifundweni sokuhlanganiswa, okuphakamisa umphumela ongeziwe noma we-synergistic kanye nokusekela ukuqhubeka kocwaningo. Ngokwesizindalwazi seBriaCell, eminye imininingwane yokuphepha nokusebenza kahle ilindeleke ngo-2022.

I-Pfizer, Inc. isanda kungena esivumelwaneni sesivivinyo somtholampilo kanye nesivumelwano sokuhlinzeka ne-Celcuity, lapho umdondoshiya wekhemisi uzohlinzeka nge-Palbociclib (Ibrance) ukuze isetshenziswe esifundweni somtholampilo sesigaba sesi-3 esiqhutshwa yi-Celcuity ngaphandle kwenkokhiso enkampanini.

Ukuhlolwa komtholampilo kwesigaba sesi-3 kulindeleke ukuthi kwethulwe engxenyeni yokuqala ka-2022 kuhlolwa ukusetshenziswa kwe-pan-PI3K/mTOR inhibitor gedatolisib (PF-05212384) ihlanganiswe ne-palbociclib kanye ne-fulvestrant ezigulini ezine-estrogen receptor (ER)–positive, HER2 -umdlavuza webele osezingeni eliphezulu awunayo. I-Celcuity izokhipha imininingwane eyengeziwe mayelana nokuhlolwa komtholampilo kulandela inkulumo kanye nempendulo elandelayo evela ku-FDA.

Ngasekupheleni kuka-2021, i-AstraZeneca PLC kanye nozakwethu u-Daiichi Sankyo bamemezele ukuthi i-European Medicines Agency (EMA) isiqinisekisile Isicelo sayo Sokuhlukahluka Kohlobo II lwe-trastuzumab deruxtecan (T-DXd; Enhertu) ukuze zelashwe ibele elithuthukile, elaphathwa ngaphambilini i-HER2-positive. iziguli ezinomdlavuza.

Ngaleso sikhathi, isiguli sokuqala esinomdlavuza webele we-HR+, i-HER2- engasebenzi we-metastatic safakwa umthamo we-datopotamab deruxtecan (DS-1062a; dato-DXd) njengengxenye yesigaba sesi-3 sesivivinyo se-TROPION-Breast01 (NCT05104866). I-DXd ADC eqondiswe ku-TROP2 okwamanje esakhiwa u-Daiichi Sankyo kanye ne-AstraZeneca okwamanje isaphenywa ocwaningweni lomhlaba wonke, olungahleliwe, olunelebula evulekile ngethamo lika-6 mg/kg uma liqhathaniswa nokukhethwa ngumseshi kwe-chemotherapy.

Enye indlela yokuthuthukisa amathuba okulwa nomdlavuza, umjaho wokuthuthukisa ukubonwa kusenesikhathi. Ngokusho kweCarol Milgard Breast Center ukutholwa kusenesikhathi kubalulekile.

I-Roche Holding AG isanda kungena ezigidini ezingama-290 zamaRandi emzuliswaneni wokuxhasa ngemali owedlule u- $1 bhiliyoni kubathuthukisi be-liquid biopsy iFreenome.